Genecast Biotechnology recently announced that a strategic cooperation had been reached with Nuohui Medical and JIAN YIBAO to establish the “Lung Cancer NGS Detection with the Medication Security Scheme” (hereinafter referred to as “LCDMS”) to help alleviate the financial burden faced by patients and improve confidence in the treatment.

The first session of the LCDMS will be used to provide security for lung cancer patients with EGFR/ALK/ROS1 gene mutation. Patients will be entitled to relevant compensation for medical expenses during the term of the scheme in cases where there has been a progression or metastasis of the tumor after having received any one of Iressa, Tagrisso, Xalkori or other cancer-targeting therapies according to diagnosis and treatment guidance, and provided they have undergone tumor gene detection with Genecast Biotechnology’s next-generation sequencing (NGS) technology and agreed on the scheme.